Abstract
Purpose
Evidence suggests patient-reported outcome (PRO) content of cancer trial protocols is frequently inadequate and non-reporting of PRO findings is widespread. This qualitative study examined the factors influencing suboptimal PRO protocol content, implementation, and reporting, and use of PRO data during clinical interactions.
Methods
Semi-structured interviews were conducted with four stakeholder groups: (1) trialists and chief investigators; (2) people with lived experience of cancer; (3) international experts in PRO cancer trial design; (4) journal editors, funding panellists, and regulatory agencies. Data were analysed using directed thematic analysis with an iterative coding frame.
Results
Forty-four interviews were undertaken. Several factors emerged that influenced effective integration of PROs into trials and subsequent findings. Participants described i) late inclusion of PROs in trial design,; ii) PROs being considered a lower priority outcome compared to survival; iii) trialists’ reluctance to collect or report PROs due to participant burden, missing data, and perceived reticence of journals to publish; iv) lack of training for staff. Strategies to address these included training research personnel and improved communication with site staff and patients regarding the value of PROs. Examples of good practice were identified.
Conclusion
Misconceptions relating to PRO methodology and their use may undermine their planning, collection, and reporting. There is a role for funding, regulatory, methodological, and journalistic institutions to address perceptions around the value of PROs, their position within the trial outcomes hierarchy, that PRO training and guidance is available, signposted, and readily accessible, with accompanying measures to ensure compliance with international best practice guidelines.